Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to people with chronic neutropenic disorders.
Pipeline
Our lead product candidate, mavorixafor, is designed to enable mobilization of immune cells from the bone marrow into the bloodstream to improve immune system function.